Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
200 participants
OBSERVATIONAL
2023-11-27
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on Gut Microbiota in Chronic HBV Infected Patients
NCT03587467
Dynamic Changes of Serum HBV RNA in Chronic Hepatitis B Patients
NCT05991531
Assessment of Hepatitis B Virus Intra-host Population and Host-specific Immune Marker Diversity
NCT02148562
Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation
NCT06853886
Establishment of Retrospective and Prospective Multicenter Cohort for Chronic Hepatitis B
NCT02263755
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HIV
Patients with HIV infection
No interventions assigned to this group
HBV
Patients with HBV infection
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Inidividuals over 19 years old
* HIV patients on antiretroviral therapy (ART)
2. HBV patients
* Individuals over 19 years old
* Chronic hepatitis B patients with either chronic hepatitis, liver cirrhosis or hepatocellular carcinoma
Exclusion Criteria
2. Individuals who have used antibiotics or steroids within 24 hours of the microbiome sample collection (excluding antiviral treatments for hepatitis B and HIV)
3. Individuals who have used vaginal or external medications, including antifungal agents, within 24 hours of microbiome sample collection
4. Those with acute illnesses, with or without fever, of moderate or severe severity; however, sampling may be postponed until the subject recovers.
5. Individuals with gastrointestinal disorders that may impact microbiome analysis and are currently medically uncontrolled or under treatment for the respective condition
6. Individuals with a positive result in a urine pregnancy test, pregnant, or breastfeeding at the time of microbiome sample collection
7. Individuals for whom medical opinions suspect that they may have an impact on the sample collection at the time of microbiome collection.
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kyunghee University Medical Center
OTHER
Hanyang University
OTHER
Kangbuk Samsung Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eun-Jeong Joo
M.D, Ph.D
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eunjeong Joo, M.D., Ph.D
Role: PRINCIPAL_INVESTIGATOR
Kangbuk Samsung Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HIVHBVgutmicrobiome
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.